3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
7
Phase 4
2
Phase 2/3
2
Phase 1/2
2
Phase NA
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Genitourinary
1
Conditions
Multiple Myeloma
1
Hodgkin Disease
1
Castrate Resistant Prostate Cancer
1
Interventions
Cisplatin
98
Gemcitabine
66
Paclitaxel
62
Carboplatin
60
Fluorouracil
59
Docetaxel
59
Capecitabine
59
Oxaliplatin
56
Cyclophosphamide
54
Radiotherapy
50
Drug Therapy
46
Bevacizumab
38
pembrolizumab
35
Dexamethasone
33
Magnetic Resonance Spectroscopy
32
Leucovorin
32
Doxorubicin
31
Cytarabine
27
Etoposide
26
Pemetrexed
25
Nivolumab
24
Methotrexate
24
Radiation
20
Vincristine
18
venetoclax
17
apatinib
17
Rituximab
17
Prednisone
17
Letrozole
17
Irinotecan
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Interventional
×
Lenograstim
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled
NCT01085058
2010-03-11
CU01
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2/3
Completed
169 enrolled